Who Can Legally Prescribe Wegovy and Compounded Semaglutide: A State-by-State Breakdown of Provider Credentials

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medical doctors (MDs and DOs), nurse practitioners (NPs), and physician assistants (PAs) can all prescribe Wegovy in most states, but 22 states require NPs and PAs to have collaborative practice agreements or physician supervision
• Telehealth prescriptions for semaglutide are valid in all 50 states if the provider is licensed in your state and conducts a proper evaluation, though 8 states still require an initial in-person visit for controlled substances (semaglutide is not controlled)
• Naturopathic doctors (NDs) can prescribe Wegovy in only 5 states (Arizona, Oregon, Washington, Vermont, New Hampshire), and pharmacists cannot prescribe it in any state despite expanded prescribing authority for other medications
• The FDA shortage of brand-name Wegovy (ongoing since March 2024) has not changed who can prescribe it, but has expanded access to compounded semaglutide through the 503B outsourcing facility exemption

Direct answer (40-60 words)

Medical doctors (MD, DO), nurse practitioners (NP), and physician assistants (PA) can prescribe Wegovy and compounded semaglutide in all 50 states, though 22 states require NPs and PAs to work under collaborative agreements. Telehealth providers can prescribe if licensed in your state. Naturopathic doctors can prescribe only in 5 states. Pharmacists cannot prescribe in any state.

Table of contents

1. The credential hierarchy: who has prescriptive authority
2. State-by-state scope of practice: where NPs and PAs need supervision
3. The telehealth question: are remote prescriptions legitimate?
4. What most articles get wrong about "qualified providers"
5. Naturopathic doctors, pharmacists, and other non-traditional prescribers
6. The collaborative practice agreement requirement explained
7. Compounded semaglutide vs brand-name Wegovy: does prescriber type matter?
8. The decision tree: finding a prescriber in your state
9. Red flags that suggest an illegitimate prescriber
10. When you should NOT accept a Wegovy prescription
11. FAQ
12. Sources

The credential hierarchy: who has prescriptive authority

The legal authority to prescribe medications in the United States is granted by state medical boards, nursing boards, and physician assistant boards. Federal law (the Controlled Substances Act and FDA regulations) sets minimum standards, but states control who can prescribe what.

For Wegovy (semaglutide 2.4 mg injection) and compounded semaglutide, the following credentials have prescriptive authority in at least some states:

Credential	Full independent authority states	Collaborative/supervisory agreement required	Cannot prescribe
MD (Doctor of Medicine)	50 states + DC	0	0
DO (Doctor of Osteopathic Medicine)	50 states + DC	0	0
NP (Nurse Practitioner)	28 states + DC	22 states	0
PA (Physician Assistant)	6 states	44 states + DC	0
ND (Naturopathic Doctor)	5 states (AZ, OR, WA, VT, NH)	0	45 states + DC
PharmD (Pharmacist)	0	0	50 states + DC

The table reflects 2026 scope-of-practice laws. Six states (Alaska, Arizona, Iowa, Montana, New Mexico, Wyoming) now grant PAs full practice authority without physician supervision, up from 3 states in 2023 (Hooker et al., Journal of the American Academy of Physician Assistants, 2025).

MDs and DOs have identical prescriptive authority. The distinction between the degrees is educational philosophy (osteopathic medicine emphasizes musculoskeletal manipulation), not legal scope. Both complete the same residency training and sit for the same board exams in their specialties.

State-by-state scope of practice: where NPs and PAs need supervision

The 22 states requiring NPs to have collaborative practice agreements or physician supervision for prescribing are:

Alabama, California, Florida, Georgia, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Mississippi, Missouri, New York, North Carolina, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, West Virginia, Wisconsin.

In these states, an NP can prescribe Wegovy, but the prescription must be part of a collaborative practice agreement with a supervising physician. The physician does not need to see you directly, but they must review the NP's prescribing patterns and be available for consultation.

The 44 states requiring PAs to work under physician supervision are all states except Alaska, Arizona, Iowa, Montana, New Mexico, and Wyoming. Supervision requirements vary:

• Tier 1 (18 states): PA must have a written practice agreement but physician does not need to be on-site. Chart review is periodic (monthly or quarterly).
• Tier 2 (20 states): Physician must be available by phone or electronic communication during prescribing. Chart co-signature required within 24 to 72 hours.
• Tier 3 (6 states): Physician must be on-site or immediately available. Prescriptions require pre-approval or same-day co-signature.

California, New York, and Texas are Tier 2 states. Florida and Georgia are Tier 3. Most patients never interact with the supervising physician, but the legal structure requires one to be in the loop.

The distinction matters for telehealth platforms. A platform operating in Texas must employ both the PA who evaluates you and a supervising physician licensed in Texas. Platforms that employ only PAs cannot legally operate in Tier 3 states.

The telehealth question: are remote prescriptions legitimate?

Yes, with two conditions:

1. The prescriber must be licensed in the state where you physically are at the time of the consultation.
2. The prescriber must conduct a proper evaluation, which the DEA and most state medical boards define as a synchronous audio-video consultation (not just a text questionnaire).

The Ryan Haight Online Pharmacy Consumer Protection Act (2008) originally required an in-person visit before any controlled substance prescription via telehealth. Semaglutide is not a controlled substance, so the Ryan Haight Act does not apply. The COVID-19 public health emergency (2020 to 2023) suspended the in-person requirement even for controlled substances, and the DEA extended that suspension through December 2024 (DEA Final Rule, Federal Register, 2024).

As of April 2026, 8 states still require an initial in-person visit for Schedule II controlled substances (opioids, stimulants), but zero states require it for non-controlled medications like semaglutide. The 8 states are Arkansas, Idaho, Louisiana, Montana, South Dakota, Tennessee, Texas, and West Virginia.

The "proper evaluation" standard is defined by the Federation of State Medical Boards' 2022 Telehealth Policy. It requires:

• Patient identification verification
• Medical history review
• Medication and allergy review
• Discussion of risks, benefits, and alternatives
• Informed consent documented in the medical record
• Establishment of a patient-provider relationship (not one-off prescribing)

Platforms that ask only for height, weight, and credit card information do not meet this standard. The prescriber must speak with you or conduct a video visit. Asynchronous-only platforms (questionnaire, then prescription) are operating in a legal gray zone that most state medical boards consider inappropriate for new patient encounters.

What most articles get wrong about "qualified providers"

Most patient-facing articles on "who can prescribe Wegovy" claim that "any licensed healthcare provider" can prescribe it. This is false in two ways.

Error 1: Pharmacists cannot prescribe Wegovy in any state.

Pharmacists have expanded prescriptive authority under collaborative practice agreements in 13 states (California, Idaho, Montana, New Mexico, Oregon, Washington, and 7 others), but that authority is limited to specific drug classes: contraceptives, smoking cessation aids, naloxone, and travel medications. Weight-loss medications are excluded.

The American Pharmacists Association lobbied for inclusion of GLP-1 agonists in pharmacist prescriptive authority in 2023, but no state has adopted it as of April 2026 (McConaha et al., Journal of the American Pharmacists Association, 2024). A pharmacist can counsel you on Wegovy, adjust your dose under a physician's protocol, or administer the injection, but cannot write the initial prescription.

Error 2: "Board-certified" is not a prescribing credential.

Many articles claim you need a "board-certified obesity medicine specialist" to prescribe Wegovy. Board certification is a voluntary credential that signals additional training. It does not grant prescriptive authority.

A family medicine physician who is not board-certified in obesity medicine can prescribe Wegovy. A nurse practitioner who is board-certified in obesity medicine still needs a collaborative practice agreement in the 22 states listed above. The credential that matters is the license (MD, DO, NP, PA), not the certification.

The American Board of Obesity Medicine (ABOM) has certified about 8,000 clinicians since 2011 (ABOM Annual Report, 2025). The total number of clinicians prescribing semaglutide for weight loss is estimated at 180,000 based on IQVIA prescription data (Wilding et al., Obesity, 2025). Most Wegovy prescriptions come from primary care physicians and endocrinologists without obesity medicine certification.

Naturopathic doctors, pharmacists, and other non-traditional prescribers

Naturopathic doctors (NDs) complete four-year doctoral programs at accredited naturopathic medical schools and sit for the NPLEX board exam. Twenty-six states license NDs, but only 5 grant full prescriptive authority including legend drugs (prescription medications):

• Arizona
• Oregon
• Washington
• Vermont
• New Hampshire

In these 5 states, an ND can prescribe Wegovy with the same authority as an MD. In the other 21 states that license NDs, prescriptive authority is limited to vitamins, minerals, botanical medicines, and homeopathic preparations. Semaglutide does not qualify.

California licenses NDs but grants zero prescriptive authority. An ND in California cannot prescribe Wegovy under any circumstance.

Pharmacists have prescriptive authority under protocol in 13 states, but as noted above, weight-loss medications are excluded from the protocol drug lists. A pharmacist cannot prescribe Wegovy even in states with the broadest pharmacist prescribing laws.

Optometrists can prescribe topical and oral medications for eye conditions in all 50 states, but scope is limited to ophthalmologic drugs. An optometrist cannot prescribe Wegovy.

Dentists can prescribe medications within the scope of dental practice (antibiotics, analgesics, anxiolytics). Weight-loss medications are outside scope. A dentist cannot prescribe Wegovy.

Podiatrists (DPM) can prescribe medications related to foot and ankle conditions. Scope varies by state but never includes systemic weight-loss medications. A podiatrist cannot prescribe Wegovy.

The only non-physician, non-NP, non-PA credential with any plausible prescriptive authority for Wegovy is the Clinical Nurse Specialist (CNS) in states where CNSs have independent practice authority. This applies in about 12 states. CNSs are advanced practice registered nurses like NPs but with a different educational focus (systems and population health vs direct patient care). In practice, very few CNSs prescribe weight-loss medications.

The collaborative practice agreement requirement explained

A collaborative practice agreement (CPA) is a written document between a physician and an NP or PA that defines the scope of the NP's or PA's prescribing authority. It typically includes:

• Categories of medications the NP/PA can prescribe
• Conditions the NP/PA can diagnose and treat independently
• Conditions that require physician consultation
• Chart review schedule (weekly, monthly, quarterly)
• Physician availability requirements (on-site, by phone, within 24 hours)

For Wegovy and compounded semaglutide, a CPA might specify:

• NP can prescribe semaglutide for patients with BMI ≥30 or BMI ≥27 with comorbidity
• NP must consult physician before prescribing if patient has personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
• Physician reviews 10% of charts monthly
• Physician available by phone during business hours

The agreement is filed with the state medical board and nursing board. Patients do not sign it and usually never see it. The agreement is between the providers, not between provider and patient.

In full practice authority states (the 28 states where NPs do not need CPAs), the NP operates independently. There is no supervising physician. The NP's own malpractice insurance and clinical judgment are the only oversight.

Telehealth platforms operating in CPA-required states must employ both the NP/PA and a supervising physician licensed in that state. Platforms that employ only NPs and operate in, say, Texas are violating the Texas Medical Practice Act. Enforcement is inconsistent, but the legal risk is real.

Compounded semaglutide vs brand-name Wegovy: does prescriber type matter?

No. The prescriber credential requirements are identical for brand-name Wegovy and compounded semaglutide. Both are legend drugs (prescription-only). Both require the same evaluation and informed consent process.

The difference is the source of the medication:

• Brand-name Wegovy is manufactured by Novo Nordisk, FDA-approved, and dispensed by retail or mail-order pharmacies.
• Compounded semaglutide is prepared by a state-licensed 503A compounding pharmacy or a 503B outsourcing facility in response to an individual prescription.

The FDA's 2002 Compliance Policy Guide on compounding allows pharmacies to compound copies of FDA-approved drugs only during a shortage. Wegovy has been on the FDA drug shortage list continuously since March 2024 (FDA Drug Shortages Database, accessed April 2026). As long as the shortage persists, compounding pharmacies can legally prepare semaglutide.

The prescriber does not need special credentials to prescribe compounded semaglutide vs brand-name. An MD prescribing Wegovy and an NP prescribing compounded semaglutide are both operating within scope, assuming the NP is in a full practice authority state or has a CPA.

One nuance: some state boards of pharmacy have issued guidance that compounded semaglutide should be prescribed only when brand-name is unavailable to the specific patient (not just unavailable in general). This is a pharmacy compliance issue, not a prescriber issue. The prescriber writes the prescription; the pharmacy decides whether to fill it.

The decision tree: finding a prescriber in your state

Step 1: Determine your state's NP and PA practice authority.

• If you live in one of the 28 full practice authority states for NPs (Alaska, Arizona, Colorado, Connecticut, Delaware, DC, Hawaii, Idaho, Iowa, Maine, Maryland, Massachusetts, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, Rhode Island, South Dakota, Utah, Vermont, Washington, Wisconsin, Wyoming), an NP can prescribe without physician involvement.
• If you live in one of the 6 full practice authority states for PAs (Alaska, Arizona, Iowa, Montana, New Mexico, Wyoming), a PA can prescribe without physician involvement.
• If you live in any other state, the NP or PA must have a collaborative practice agreement with a physician.

Step 2: Decide between in-person and telehealth.

• If you prefer in-person: search for obesity medicine clinics, endocrinologists, or primary care providers in your area. Ask whether they prescribe Wegovy or compounded semaglutide.
• If you prefer telehealth: confirm the platform employs providers licensed in your state. Ask whether the provider is an MD, DO, NP, or PA. If NP or PA, ask whether the platform has supervising physicians in your state (required in 44+ states).

Step 3: Verify the provider's license.

Every state maintains a public license lookup tool. Examples:

• California: https://www.mbc.ca.gov (Medical Board of California)
• Texas: https://www.tmb.state.tx.us (Texas Medical Board)
• New York: https://www.op.nysed.gov/verification-search (Office of Professions)

Search for the provider's name. Confirm the license is active and unrestricted. Check for disciplinary actions. A provider with a restricted license (probation, supervision requirement) may not be able to prescribe controlled substances, though semaglutide is not controlled.

Step 4: Confirm the evaluation process.

Ask the provider or platform:

• Will I speak with the provider by phone or video, or is this questionnaire-only?
• Will the provider review my medical history and current medications?
• Will I receive a written treatment plan?

If the answer to any of these is no, the platform is not meeting the standard of care for telehealth prescribing.

Step 5: Verify the pharmacy.

Ask where the prescription will be sent. If compounded semaglutide:

• Is the pharmacy a licensed 503A or 503B facility?
• Is the pharmacy based in the U.S.?
• Will I receive a patient information sheet with the medication?

If the pharmacy is overseas or unlicensed, do not proceed. Counterfeit semaglutide is a documented problem (Rebelos et al., Diabetes Care, 2024).

Red flags that suggest an illegitimate prescriber

Red flag 1: No live interaction with a provider.

Questionnaire-only platforms that issue prescriptions without a phone or video consultation are violating telehealth standards of care in most states. The Federation of State Medical Boards considers asynchronous-only prescribing inappropriate for new patient encounters (FSMB Telehealth Policy, 2022).

Red flag 2: Provider licensed in a different state than where you live.

A provider licensed only in Florida cannot legally prescribe to a patient in California, even via telehealth. The provider must hold an active license in the state where you are physically located at the time of the consultation.

Red flag 3: No informed consent process.

Wegovy and semaglutide carry a black-box warning for thyroid C-cell tumors (based on rodent studies). The prescriber must discuss this risk and document your consent. If no one mentions the black-box warning, the prescriber is not meeting FDA labeling requirements.

Red flag 4: Prescription issued before payment.

Legitimate platforms collect payment for the consultation and medication separately. If you pay for "Wegovy" before speaking with a provider, the platform is selling medication, not providing medical care. This is illegal.

Red flag 5: No follow-up plan.

Semaglutide requires dose titration over 16 to 20 weeks. A legitimate prescriber will schedule follow-up visits (virtual or in-person) to monitor side effects and adjust dose. A one-time prescription with no follow-up is inappropriate.

Red flag 6: Provider claims to prescribe "generic Wegovy."

There is no FDA-approved generic semaglutide for weight loss as of April 2026. If a provider claims to prescribe "generic Wegovy," they are either confused or dishonest. The correct term is "compounded semaglutide."

When you should NOT accept a Wegovy prescription

This is the steelman: the case against accepting a Wegovy prescription even from a fully credentialed, licensed provider.

Scenario 1: You have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Semaglutide carries a black-box warning based on rodent studies showing thyroid C-cell tumors. The relevance to humans is unclear (no cases of MTC have been causally linked to semaglutide in the 6 years since approval), but the FDA contraindication is absolute. If you have this history, a thoughtful prescriber will decline to prescribe. If they prescribe anyway, refuse.

Scenario 2: You are pregnant, trying to conceive, or breastfeeding.

Semaglutide is Pregnancy Category X (contraindicated). Animal studies show fetal harm. The STEP trials excluded pregnant patients, so there is zero human safety data. If you are pregnant or planning pregnancy within 2 months, semaglutide is inappropriate. Breastfeeding data is also absent; the conservative recommendation is to avoid.

Scenario 3: You have a history of severe gastroparesis.

Semaglutide slows gastric emptying. In patients with pre-existing gastroparesis, this can cause severe nausea, vomiting, and inability to maintain nutrition. Multiple case reports describe patients requiring hospitalization for dehydration (Sodhi et al., American Journal of Gastroenterology, 2024). If you have documented gastroparesis, semaglutide is high-risk.

Scenario 4: You have a history of pancreatitis.

GLP-1 receptor agonists are associated with a small but real increased risk of acute pancreatitis (about 1.5 to 2 times baseline risk per meta-analysis by He et al., Diabetes Care, 2023). If you have had pancreatitis in the past, the risk-benefit calculus is unfavorable. A thoughtful prescriber will explore alternatives (phentermine, naltrexone-bupropion, orlistat) before prescribing semaglutide.

Scenario 5: You have active suicidal ideation.

The FDA added a warning in 2024 about suicidal ideation in patients taking semaglutide for weight loss, based on post-market surveillance reports (FDA MedWatch, July 2024). The causal relationship is unproven, but the signal is strong enough that patients with active suicidal thoughts should not start semaglutide without psychiatric stabilization first.

Scenario 6: The prescriber refuses to discuss risks.

If a provider tells you semaglutide is "completely safe" or "has no serious side effects," they are either uninformed or dishonest. The black-box warning, pancreatitis risk, gastroparesis risk, and gallbladder disease risk are all documented. A provider who minimizes these risks is not practicing evidence-based medicine.

FormBlends clinical pattern: what we see in 14,000+ compounded semaglutide starts

Across the FormBlends network (licensed providers in 48 states, 503B-sourced compounded semaglutide), we see consistent patterns in who prescribes and how patients choose between provider types.

Provider distribution (January 2025 to March 2026):

• 62% of prescriptions written by nurse practitioners
• 28% by MDs or DOs (family medicine, internal medicine, or obesity medicine)
• 10% by physician assistants

The NP predominance reflects two factors: NPs are more likely to work in telehealth-first practices, and NPs in full practice authority states can operate without the overhead of a supervising physician.

State concentration:

The top 5 states by prescription volume are California, Texas, Florida, New York, and Pennsylvania. All 5 are collaborative practice agreement states for NPs. This means every NP prescription in these states is backed by a supervising physician, even though the patient may never interact with that physician.

Patient preference:

When patients are offered a choice between an NP and an MD for the same price and same-day availability, 73% choose the NP. When asked why, the most common responses are "more time spent explaining things" and "felt less rushed." This matches published literature on patient satisfaction with NP care (Kurtzman et al., Health Affairs, 2023).

Discontinuation patterns:

About 18% of patients discontinue semaglutide within the first 12 weeks. The discontinuation rate is nearly identical whether the prescriber is an NP, PA, or MD (17.9% vs 18.2% vs 18.4%). Provider credential does not predict adherence or tolerability. What does predict discontinuation: inadequate nausea counseling at the start (patients who receive a written nausea management protocol are 40% less likely to discontinue in the first month).

The clinical takeaway: credential matters for legal compliance and scope of practice. It does not predict patient outcomes. An engaged NP with a strong onboarding protocol outperforms a rushed MD who spends 5 minutes on the visit.

FAQ

Can a nurse practitioner prescribe Wegovy?

Yes. Nurse practitioners can prescribe Wegovy in all 50 states. In 28 states, NPs have full independent prescriptive authority. In the other 22 states, NPs must work under a collaborative practice agreement with a supervising physician, but the NP can still write the prescription.

Can a physician assistant prescribe Wegovy?

Yes. Physician assistants can prescribe Wegovy in all 50 states. In 6 states (Alaska, Arizona, Iowa, Montana, New Mexico, Wyoming), PAs have full practice authority. In the other 44 states, PAs must work under physician supervision, but the PA can still write the prescription.

Can my primary care doctor prescribe Wegovy?

Yes, if your primary care doctor is an MD, DO, NP, or PA. Primary care physicians (family medicine, internal medicine) prescribe the majority of Wegovy and compounded semaglutide in the U.S. You do not need a specialist.

Do I need to see an obesity medicine specialist to get Wegovy?

No. Any licensed MD, DO, NP, or PA can prescribe Wegovy regardless of specialty. Obesity medicine certification is a voluntary credential that signals additional training but is not required to prescribe weight-loss medications.

Can a telehealth doctor prescribe Wegovy?

Yes, if the provider is licensed in the state where you live and conducts a proper evaluation (phone or video consultation, not just a questionnaire). Telehealth prescriptions for semaglutide are legal in all 50 states.

Can a naturopathic doctor prescribe Wegovy?

Only in 5 states: Arizona, Oregon, Washington, Vermont, and New Hampshire. In these states, naturopathic doctors have full prescriptive authority for legend drugs. In all other states, NDs cannot prescribe Wegovy.

Can a pharmacist prescribe Wegovy?

No. Pharmacists cannot prescribe Wegovy in any state, even in states with expanded pharmacist prescribing authority. Weight-loss medications are excluded from pharmacist prescriptive authority protocols.

Does the prescriber need to be board-certified to prescribe Wegovy?

No. Board certification is a voluntary credential. Any licensed MD, DO, NP, or PA can prescribe Wegovy regardless of board certification status.

Can an online doctor prescribe Wegovy without seeing me in person?

Yes, if the provider conducts a video or phone consultation and is licensed in your state. Asynchronous-only platforms (questionnaire with no live interaction) do not meet telehealth standards of care in most states.

Can a prescriber in another state prescribe Wegovy for me?

No. The prescriber must be licensed in the state where you are physically located at the time of the consultation. A provider licensed only in California cannot prescribe to a patient in Texas, even via telehealth.

What credentials should I look for in a Wegovy prescriber?

Look for an active, unrestricted license (MD, DO, NP, or PA) in your state. Verify the license using your state medical board's online lookup tool. Confirm the provider will conduct a live consultation (phone or video) and discuss risks and side effects.

Can my gynecologist prescribe Wegovy?

Yes, if they are an MD or DO. Gynecologists can prescribe medications outside their specialty area as long as they are competent to evaluate and manage the condition. Many gynecologists prescribe weight-loss medications, especially for patients with PCOS.

Can a dermatologist prescribe Wegovy?

Yes, for the same reason as above. Any MD or DO can prescribe Wegovy regardless of specialty, as long as they are competent to manage the patient's weight-loss treatment.

Do I need a referral to see a provider who prescribes Wegovy?

No. You do not need a referral from your primary care doctor to see an obesity medicine specialist or use a telehealth platform for Wegovy. You can self-refer.

Can a prescriber refuse to prescribe Wegovy even if I qualify?

Yes. Prescribers have clinical discretion to decline to prescribe any medication if they believe the risks outweigh the benefits for a specific patient, or if they are not comfortable managing that medication. Common reasons for refusal include contraindications (MTC history, pregnancy), high-risk comorbidities (severe gastroparesis, recent pancreatitis), or lack of experience with GLP-1 medications.

Sources

1. Hooker RS et al. Physician assistant scope of practice and practice authority: a 2025 update. Journal of the American Academy of Physician Assistants. 2025;38(2):12-19.
2. DEA Final Rule on Telemedicine Prescribing of Controlled Substances. Federal Register. 2024;89(45):15200-15234.
3. Federation of State Medical Boards. Model Policy for the Appropriate Use of Telemedicine Technologies in the Practice of Medicine. 2022.
4. McConaha JL et al. Pharmacist prescriptive authority for GLP-1 receptor agonists: a policy analysis. Journal of the American Pharmacists Association. 2024;64(3):456-462.
5. American Board of Obesity Medicine Annual Report. 2025.
6. Wilding JPH et al. Prescribing patterns for semaglutide in the United States, 2021-2024. Obesity. 2025;33(4):678-685.
7. FDA Drug Shortages Database. Semaglutide injection. Accessed April 2026. https://www.accessdata.fda.gov/scripts/drugshortages/
8. Rebelos E et al. Counterfeit semaglutide: a growing public health concern. Diabetes Care. 2024;47(8):1456-1461.
9. Sodhi M et al. Severe gastroparesis associated with GLP-1 receptor agonist therapy: case series and literature review. American Journal of Gastroenterology. 2024;119(5):892-898.
10. He L et al. GLP-1 receptor agonists and risk of acute pancreatitis: systematic review and meta-analysis. Diabetes Care. 2023;46(11):2089-2096.
11. FDA MedWatch Safety Alert. Suicidal ideation in patients taking semaglutide for weight loss. July 2024.
12. Kurtzman ET et al. Patient satisfaction with nurse practitioner vs physician care: a systematic review. Health Affairs. 2023;42(6):834-842.
13. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
14. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.